Omid Hamid MD
Chief of Research and Immunotherapy • ImmunoOncology • Phase I Clinical Trials • Melanoma • Cutaneous Oncology
Last synced from Twitter 2m ago
Humanized Monoclonal Antibodies: Worldwide - Expertscape.com
Best hospitals and doctors for Antibodies, Monoclonal, Humanized in the world
Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer | NEJM
Special Report from The New England Journal of Medicine — Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
The dose-escalation dosing strategy represents an alternative approach for optimising
regorafenib dosing with comparable activity and lower incidence of adverse events
and could be implemented in clinical practice on the basis of these data.
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432
AbstractBackground. High tumor mutational burden (TMB-H) is correlated with enhanced objective response rate (ORR) and progression-free survival (PFS) for cert
New STARs of Cancer Immunotherapy Research
Five U.S. scientists have been awarded $1.25 million each to carry out high-risk, high-reward cancer immunology research with potential to transform cancer treatment.
γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer
This Review discusses the rapidly accumulating preclinical evidence in support of antitumour, but also of some pro-tumour, roles for γδ T cells in cancer progression. It also outlines the potential for manipulating their functions for use as an...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy | Merck Newsroo
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S.
OncLive® Announces Global Expo Challenge: Innovative Technology in Cancer Care
From BioPortfolio: Submissions can be submitted until Aug. 1 OncLive®, the nation’s leading digital resource focused on providing oncology professionals with the most cu...
United States Intergroup E1609 A phase III randomized study of adjuvant ipilimumab 3 or 10 mg kg versus high-dose interferon-α2b for resected high-risk melanoma
Ahmad Tarhini Md, PhD of the Winship Cancer Center discusses the United States Intergroup E1609 A phase III randomized study of adjuvant ipilimumab 3 or 10 mg kg versus high-dose interferon-α2b for resected high-risk melanoma.
Background: Phase...
Paying for Clinical Trials
Learn about the different types of costs related to taking part in a clinical trial, and who is expected to pay for which costs. For more on clinical trials,...
Omid Hamid MD
#clinical trials are important, know your rights and your responsibilities
34d
Novel Therapies for Metastatic Melanoma - Omid Hamid MD
Omid Hamid MD, Chief of Translational Research and Immunotherapy at The Angeles Clinic and Research Institute discusses new and novel Immunotherapies for Met...
Omid Hamid MD
Explore novel therapies for #melanoma. Discussion from @AIMatMelanoma @angelesclinic patient symposium youtu.be/fbSHUEbhTho pic.twitter.com/V0Kk6kiSao
36d
Sunburn Tattoos Are the Latest Viral Trend You Should Never, Ever Try
Sunburn tattoos are the latest viral trend that you should never, ever try. Here, dermatologists explain why.
Exploring Durable Responses With Liso-Cel for Relapsed/Refractory CLL
Matthew S. Davids, MD, MMSc, discusses the significance of the findings from TRANSCEND CLL 004, a phase I/II trial investigating the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed or refractory chronic lymphocytic leukemia.
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations - Full Text View - ClinicalTrials.gov
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations - Full Text View.
Omid Hamid MD
#immunotherapy for #prostatecancer open @angelesclinic: @parkerici Platform Study for Prostate Researching Translational Endpoints Correlated to Response (PORTER) clinicaltrials.gov/ct2/show/NCT03…
theangelesclinic.org
37d
Adjuvant Treatment for Melanoma
Dr. Alexandra Gangi, Assistant Professor of Surgical Oncology at Cedars Sinai Medical Center discusses the evolving role of adjuvant therapy for Melanoma
Precision Medicine - Chioces Through Your Pathology Report
Discussion of the role of Precision Medicine in treatment decision making and its intersection with ImmunoOncology. Dr. Samuel Klempner discusses how clinica...
Omid Hamid MD
Confused about your pathology report and tumor sequencing? @KlempnerSam discusses how #PrecisionMedicine and #nextgeneration sequencing play a role @angelesclinic youtube.com/watch?v=dpivAt… pic.twitter.com/inGJxhWjYM
36d
Surgery in Melanoma - Mark Faries MD, The Angeles Clinic and Research Institute
Mark Faries MD, Director of Surgical oncology at The Angeles Clinic and Research Institute discusses the role of Surgery in Malignant Melanoma in the era of ...
2
Omid Hamid MD
Watch @MarkFariesMD discuss Surgical Breakthroughs in Melanoma from @AIMatMelanoma @angelesclinic symposium
youtube.com/watch?v=n05z3u… pic.twitter.com/HreGiCo5lV
37d
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Triple therapy combining BRAF and MEK inhibitors with immune checkpoint blockade may benefit a subset of patients with BRAFV600-mutated metastatic melanoma.
Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Omid Hamid MD
Data from our phase 1 trial of sting agonist and Pd1 in naïve and refractory solid tumors @angelesclinic @Novartis #worktodo
44d